OBJECTIVE：To observe therapeutic efficacy and safety of telbivudine combined with adefovir dipivoxil in long-term treatment of active hepatitis B cirrhosis. METHODS：76 patients with active hepatitis B cirrhosis in our hospital were randomly divided into observation group and control group，with 38 cases in each group. Control group was treated with adefovir dipivoxil 10 mg，qd；observation group was additionally treated with telbivudine 600 mg，qd，on the basis of control group. Both groups received 2-year consecutive treatment. TBIL，ALB，ALT，AST，rate of HBV-DNA negative conversion and serum virological index were compared between 2 groups after treatment，and clinical efficacy and ADR were also compared between 2 groups. RESULTS：After treatment，the levels of AST，ALB，ALT and TBIL in observation group were significantly better than the control group，with statistical significance（P＜0.05）；the rate of HBV-DNA negative conversion，the decreased of serum virus in observation group were significantly higher than control group after 1 and 2 years treatment，with statistical significance（P＜0.05）. The total effective rate of observation group was significantly higher than that of control group，with statistically significance（P＜0.05）. No obvious ADR was found in 2 groups. CONCLUSIONS：Telbivudine combined with adefovir dipivoxil can significantly improve the liver function of patients with hepatitis B cirrhosis and have good long-term therapeutic efficacy with high safety.